Paclitaxel Injection IP 260 mg 43.4 ml

Paclitax 260 mg Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer.

Paclitax 260 mg Injection 43.4 ml contains ‘Paclitaxel’, which works by stopping cell division and preventing the growth of certain cancer cells.

In some cases, Paclitax 260 mg Injection 43.4 ml may cause common side effects, such as nausea, vomiting, mild diarrhoea, and joint or muscle pain. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.

Consult your doctor if you are pregnant, breastfeeding, think you may be pregnant or are planning pregnancy. Paclitax 260 mg Injection 43.4 ml is not recommended for children below 18 years. Inform your doctor about your health condition and medications to rule out any side effects.

Paclitax 260 mg Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer. It may also be used when other treatments have failed or in combination with other treatments. Paclitax 260 mg Injection 43.4 ml may also be indicated in patients with Kaposi’s sarcoma (cancer that develops from the cells that line lymph or blood vessels) associated with AIDS (Acquired Immuno-Deficiency Syndrome), where other treatments have not been effective. Paclitax 260 mg Injection 43.4 ml contains ‘Paclitaxel’, which works by preventing the growth of certain cancer cells.